本帖最后由 StephenW 于 2011-6-3 15:08 编辑
TABLE 1 | Novel drugs in clinical trials with issued compound patents in the US or EU
From the following article:Innovative drug R&D in China Jingzong Qi, Qingli Wang, Zhenhang Yu, Xin Chen & Fengshan Wang Nature Reviews Drug Discovery 10, 333-334 (May 2011) doi:10.1038/nrd3435
Compound | Developer | Therapeutic area | Patent | Stage | Iptakalim | Nhwa | Cardiovascular | EU | III | Aildenafil | Wannianchun | Genitourinal | US | III | Cymipristone | Xianju | Genitourinal | US/EU | III | Icotinib | Beida | Cancer | US | III | rSIFN | Huiyang | Cancer | US/EU | III | Sulcardine | SIMM | Cardiovascular | US/EU | II | Trichosanthin | Xiangtianmu | Infection | US | II | Sifuvirtide | FusoGen | Infection | US/EU | II | Chiglitazar | Chipscreen | Endocrine/metabolism | US | II | Tyroservatide | Yitai | Cancer | US | II | Trantinterol | Jiutai | Respiratory | US/EU | II | Chidamide | Chipscreen | Cancer | US | II | Buagafuran | SIMM | Central nervous system | US | I | Ethaselen | Qizheng | Cancer | US | I | Nemonoxacin | Huayu | Infection | US/EU | I | Albuvirtide | Frontier | Infection | US | I | Thienorphine | IPT | Central nervous system | US/EU | I | Triptolide | SIMM | Musculoskeletal | US | I | Novaferon | Genova | Cancer | US | I | PEG-rhArginase | BCT | Cancer | EU | I | yPEG–rhGCSF | Amoytop | Cancer | EU | I | yPEG–rhGH | Amoytop | Endocrine/metabolism | EU | I | Citricplatin | Sansiweier | Cancer | US/EU | I | yPEG–rhIFNα2a | Amoytop | Infection | EU | I | EU, European Union; GCSF, granulocyte colony-stimulating factor; GH, growth hormone; IPT, Institute of Pharmacology and Toxicology; PEG, polyethylene glycol; rh, recombinant human; rSIFN, recombinant super compound interferon (IFN); SIMM, Shanghai Institute of Materia Medica; SIPI, Shanghai Institute of Pharmaceutical Industry; US, United States of America; yPEG, Y-shape branched PEG. |
|